Primary Biliary Cholangitis (PBC) is a chronic cholestatic disease with a progressive course that may extend over many decades. It is considered an autoimmune disease because of its hallmark serologic signature, antimitochondrial antibody (AMA), and specific bile duct pathology. The rate of progression varies greatly among individual patients. Over the past decades, there have been many changes in the diagnosis and management of PBC. More patients are being recognized with earlier‐stage disease, and many of these patients respond well to medical therapy. In both Europe and North America, the number of liver transplants for PBC is falling. However, the overall prevalence of the disease is increasing.
When PBC is very severe, it can lead to yellow discoloration of the skin (jaundice). If PBC is untreated, it can lead to cirrhosis, or scarring of the entire liver, which can lead to liver failure. PBC is divided into four stages, with stage 1 being early disease, where this is no significant scarring, to stage 4, or which is defined by cirrhosis.
The DelveInsight Primary Biliary Cholangitis epidemiology report gives a thorough understanding of the Primary Biliary Cholangitis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis.
It also provides treatment algorithms and treatment guidelines for Primary Biliary Cholangitis in the US, Europe, and Japan. The report covers the detailed information of the Primary Biliary Cholangitis epidemiology scenario in seven major countries (US, EU5, and Japan).
Key Highlights Of The Report
According to the National Organization for Rare Disorders (NORD), it has been estimated that PBC is one of the most common autoimmune diseases, affecting nearly 1 in 1000 women over the age of 40.
According to “Orphanet”, PBC affected individuals are usually in their fifth to seventh decades of life at time of diagnosis, and 90% are women. Annual incidence is estimated at between 1/1,430,000 and 1/20,400 inhabitants and prevalence at between 1/150,000 and 1/1,063 inhabitants (depending on age and sex).
As per one study titled “Sex Differences associated with primary biliary cirrhosis” conducted by Daniel S. Smyk et al. (2012), out of all the studied patients, approximately 7‐11% of PBC patients were found to be males.
As per the study conducted by Teru Kumagi et al., titled “Primary biliary cirrhosis”, Primary biliary cirrhosis prevalence is estimated to be between 6.7 and 940 cases per million‐population (the latter in women >40 yrs old in United Kingdom), while its incidence is estimated to be between 0.7 and 49 cases per million‐population per year.
Request for Sample Pages:
https://delveinsight.com/sample-request/primary-biliary-Cholangitis-epidemiology-forecast
Primary Biliary Cholangitis Epidemiology
Delveinsight’s Primary Biliary Cholangitis epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries.
The Primary Biliary Cholangitis epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM.
The Primary Biliary Cholangitis epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030.
It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Scope of the Report
The report provides insight into the historical and forecasted patient pool of Primary Biliary Cholangitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
The report assesses the disease risk and burden and highlights the unmet needs of Primary Biliary Cholangitis.
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
The Primary Biliary Cholangitis report provides a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
The Primary Biliary Cholangitis Epidemiology Report and Model provide an overview of the risk factors and global trends of Primary Biliary Cholangitis in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan).
The report provides the segmentation of the Primary Biliary Cholangitis epidemiology.
Key Questions Covered In The Primary Biliary Cholangitis Report Include:
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Primary Biliary Cholangitis?
What are the key findings pertaining to the Primary Biliary Cholangitis epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
What would be the total number of patients of Primary Biliary Cholangitis across the 7MM during the forecast period (2017-2030)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
What is the disease risk, burden and unmet needs of the Primary Biliary Cholangitis?
What are the currently available treatments of Primary Biliary Cholangitis?
Key Benefit of Primary Biliary Cholangitis Epidemiology Report
The Primary Biliary Cholangitis Epidemiology report will allow the user to –
Develop business strategies by understanding the trends shaping and driving the global Primary Biliary Cholangitis market
Quantify patient populations in the global Primary Biliary Cholangitis market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Primary Biliary Cholangitis therapeutics in each of the markets covered
Understand the magnitude of Primary Biliary Cholangitis population by its epidemiology
The Primary Biliary Cholangitis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Table of Contents
-
Key Insights
-
Executive Summary of Primary Biliary Cholangitis
-
Primary Biliary Cholangitis Disease Background and Overview
-
Primary Biliary Cholangitis Sign and Symptoms
-
Primary Biliary Cholangitis Pathophysiology
-
Primary Biliary Cholangitis Risk Factors
-
Primary Biliary Cholangitis Diagnosis
-
Primary Biliary Cholangitis Patient Journey
-
Primary Biliary Cholangitis Epidemiology and Patient Population
-
Primary Biliary Cholangitis Treatment Algorithm, Current Treatment, and Medical Practices
-
KOL Views on Primary Biliary Cholangitis
-
Primary Biliary Cholangitis Unmet Needs
-
Appendix
-
DelveInsight Capabilities
-
Disclaimer
*The table of contents is not exhaustive; will be provided in the final report
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Related Reports:
Primary Biliary Cholangitis Market Insight, Epidemiology and Market Forecast -2030
DelveInsight’ s Primary Biliary Cholangitis Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology.
Primary Biliary Cholangitis Pipeline Insights, 2020
Primary Biliary Cholangitis Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Primary Biliary Cholangitis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/